Webcast: Cardiometabolic therapies at scale and their implications for drug delivery

As cardiometabolic therapies reach broader and more diverse patient populations, driven in part by the rapid growth of peptide-based treatments, expectations are shifting toward delivery systems that support safe, reliable use over time while addressing long-term sustainability. 

In a conversation with Drug Delivery Leader, SHL Medical’s Head of Portfolio Strategy, Courtney Nicholas Sutton joins Chief Editor Tom von Gunden to discuss how these dynamics are shaping drug delivery strategy and device design. 

The conversation explores how cardiometabolic treatment pathways are evolving and what is driving new delivery approaches, including multi-dose systems. It also addresses the limitations of conventional pen systems as therapies scale, particularly in supporting patient safety. It then turns to the role of device architecture in shaping not only the patient experience but also resource efficiency and the broader sustainability impact of the delivery system.

For pharma teams working in cardiometabolic and peptide-based programs, this session provides perspectives on aligning delivery system strategy with changing therapeutic demands and patient realities.  

Access the full interview via Drug Delivery Leader.  

For additional insight into SHL Medical’s work in cardiometabolic drug delivery, please contact us.